Rivastigmine and Oxybutynin Interaction

Drug interaction information between Rivastigmine and Oxybutynin.

Rivastigmine and Oxybutynin have a documented minor interaction in FDA labeling.

FDA drug labeling documents a minor-severity interaction between Rivastigmine and Oxybutynin. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Rivastigmine

Acetylcholinesterase Inhibitor

Drug B

Oxybutynin

Anticholinergic / Antispasmodic

How They Interact

These drugs have opposite effects on the body. Rivastigmine can prevent oxybutynin from working the way it is supposed to.

FDA Label Information

7.2 Cholinomimetic and Anticholinergic Medications Rivastigmine tartrate may increase the cholinergic effects of other cholinomimetic medications and may also interfere with the activity of anticholinergic medications (e.g., oxybutynin, tolterodine).

Frequently Asked Questions

What SPL severity band is on file for Rivastigmine + Oxybutynin?

Compiled FDA labeling labels this pair minor. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Oxybutynin has 7 labeled pairs on file vs Rivastigmine's 4. In the minor band specifically: Rivastigmine has 3 (also Atenolol, Tolterodine); Oxybutynin has 7 (also Ketoconazole, Erythromycin, Clarithromycin, Itraconazole).

What mechanism field is on file for Rivastigmine and Oxybutynin?

These drugs have opposite effects on the body. Rivastigmine can prevent oxybutynin from working the way it is supposed to.

Oxybutynin's labeled portfolio outnumbers Rivastigmine

SPL source-record counts only. This page's band is minor · classes on file: Rivastigmine (Acetylcholinesterase Inhibitor); Oxybutynin (Anticholinergic / Antispasmodic).

Rivastigmine

0 major · 1 moderate · 3 minor · 4 total

Oxybutynin

0 major · 0 moderate · 7 minor · 7 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.